RSHF in Colorectal Cancer (RS CAMPTO)
CLINICAL MULTICENTER STUDY OF PHASE II AND RADIOBIOLOGY ASSESSING Hypofractionated Stereotactic Radiotherapy With Irinotecan (Campto) IN THE TREATMENT OF LIVER METASTASIS AND / OR PULMONARY, Unoperated or Recurrent After Surgery of a Colorectal Cancer
Sponsor: Institut Cancerologie de l'Ouest
Listed as NCT01220063, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by Institut Cancerologie de l'Ouest, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Sep 2018 — Feb 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Cancerologie de l'Ouest
For direct contact, visit the study record on ClinicalTrials.gov .